Roche drug succeeds in hard-to-treat form of multiple sclerosis

Switzerland’s Roche has a potential new multi-billion-dollar drug to help it diversify beyond cancer treatments following the success of ocrelizumab against a hard-to-treat type of multiple sclerosis. The injectable antibody medicine is the first product to sh... More »